ClinicalTrials.gg
CompletedNCT06847789Updated Feb 26, 2025

Evaluation of the Tensi+ Device for the Treatment of Overactive Bladder

An observational study in Overactive Bladder, sponsored by Stimuli Technology. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by Stimuli Technology · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
79
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Urinary Bladder, Overactive with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Urinary Bladder, Overactive · France.

Enrollment
8th of 13
79 · median 100
Started
2022
the only one that year
Observational
13 of 53
1 open now
Registered
45th of 53
by date

Among the 53 studies in Urinary Bladder, Overactive with a site in France, this one is the 8th largest by enrollment of the 13 observational ones that give a count, is the only one that started in 2022, is one of 13 observational ones, and was the 45th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

6 of the 53 studies in Urinary Bladder, Overactive with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Urinary Bladder, Overactive with a site in France, or all of them as a file.
02

Study summary

Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management. While effectiveness of TC-pTNS has been demonstrated in the literature, the success rate is heterogeneous, depending on the clinical picture. In an effort to ascertain clearly the efficacy of Tensi+ device, as well as its safety of use and assess comfort of use, the present study will evaluate the results of Tensi+ treatment in real life conditions in a prospective study. The main objective is to assess the efficacy (actual clinical benefit) of TC-pTNS with Tensi+ device for management of overactive bladder in an adult population at 3 months.

Included patients are prescribed a treatment with Tensi+ for 3 months. An evaluation visit is scheduled at 3 months. In treatment is continued, a follow-up visit is scheduled at 6 months.

Primary outcome measure

Success at 3 months defined as a composite parameter:

(i) Objective improvement, with at least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary AND (ii) Subjective improvement, with patient Global Impression of Improvement score of 1 or 2 Time point(s) at which primary outcome measure is assessed : 3 months Secondary outcome measures (i) Evaluation of urinary symptoms based on bladder diary parameters (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire (ii) Evaluation of adverse events (iii) Patient-reported Outcomes Measures (PROMs): Comfort of use (VAS in deciles), recommendation to another patient (binary), consumer grading regarding device usability details (iv) Quality of life measures (OABq questionnaire, VAS scale) (vii) Assessment of treatment persistence Time point(s) at which Secondary outcome measure is assessed* : at 3 months and 6 months

Inclusion criteria : Age ≥ 18 years Overactive bladder symptoms

Number of subjects : 100

03

Conditions studied

  • Overactive Bladder

Keywords

  • Urology
  • TENS
  • Overactive bladder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Age ≥ 18 years Overactive bladder symptoms

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients suffering from Overactive bladder symptoms

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients with active implantable device or ankle orthopedic implant,
  • Ankle articular diseases.
  • Prior treatment with transcutaneous PTNS or percutaneous PTNS (any time),
  • Sacral neuromodulation (anytime) or,
  • Intradetrusor botulinum toxin injection within the past 6 months
  • Antimuscarinic use within 1 month prior to the study
  • 24hour diuresis > 2800cc on bladder diary
  • Known bladder disease
  • Active urinary tract infection
  • PVR> 150 ml
  • Pelvic organ prolapse stage >2
  • Predominant stress urinary incontinence
  • Cognitive impairment
  • Inability to use the device without a third party
  • Inability to complete a bladder diary
  • No health insurance coverage
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
79 participants (actual)
Patient registry
No

Interventions

  • DeviceTensi+

    Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.

06

What researchers measure

Primary outcomes

  1. Objective improvement

    At least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary

    Time frame: At 3 months

  2. Subjective improvement

    Patient Global Impression of Improvement score of 1 or 2

    Time frame: At 3 months

Secondary outcomes

  1. Evaluation of urinary symptoms

    Bladder diary parameters evaluation (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire

    Time frame: At 3 months and 6 months

  2. Evaluation of adverse events

    Questions to be asked to patients at 3 months and 6 months if there were any adverse events during treatment

    Time frame: At 3 months and 6 months

  3. Patient-reported Outcomes Measures (PROMs)

    Comfort of use, recommendation to another patient (binary), consumer grading regarding device usability details

    Time frame: At 3 months and 6 months

  4. Quality of life measures

    By filling up OABq questionnaire and VAS scale

    Time frame: At 3 months and 6 months

  5. Assessment of treatment persistence

    Time frame: At 3 months and 6 months

07

Study locations

1 site
  • CHU Rouen
    Rouen, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2023, 11 months.

Of 59 observational studies under Urinary Bladder, Overactive, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2022
First posted
Feb 26, 2025
StartActual
May 25, 2022
Primary completionActual
May 15, 2023
CompletionActual
May 15, 2023
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847789
Lead sponsor
Stimuli Technology
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
May 25, 2022
Primary completion
May 15, 2023
Completion
May 15, 2023
Last update
Feb 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion